Belotecan

Generic Name
Belotecan
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H27N3O4
CAS Number
256411-32-2
Unique Ingredient Identifier
27Z82M2G1N
Background

Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer.

Associated Conditions
-
Associated Therapies
-

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-06-28
Last Posted Date
2016-09-22
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
141
Registration Number
NCT01630018
Locations
πŸ‡°πŸ‡·

Seoul National University Hospital, Seoul, Seoul Metropolitan, Korea, Republic of

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-12-23
Last Posted Date
2018-12-27
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
164
Registration Number
NCT01497873
Locations
πŸ‡°πŸ‡·

National Cancer Center, Goyang, Korea, Republic of

πŸ‡°πŸ‡·

Chungbuk University Hospital, Daegu, Korea, Republic of

πŸ‡°πŸ‡·

Keimyung University Dongsan Center, Daegu, Korea, Republic of

and more 11 locations

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-12-01
Last Posted Date
2016-01-28
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
52
Registration Number
NCT01022671

Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient

First Posted Date
2009-01-22
Last Posted Date
2021-08-09
Lead Sponsor
Chonnam National University Hospital
Target Recruit Count
147
Registration Number
NCT00826644
Locations
πŸ‡°πŸ‡·

Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of

Β© Copyright 2024. All Rights Reserved by MedPath